Aytu BioPharma, Inc. (LON:0A8M)

Aytu BioPharma Statistics

Total Valuation

Aytu BioPharma has a market cap or net worth of GBP 17.31 million. The enterprise value is 10.59 million.

Market Cap	17.31M
Enterprise Value	10.59M

Important Dates

The last earnings date was Tuesday, February 3, 2026.

Earnings Date	Feb 3, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	6.17M
Shares Outstanding	n/a
Shares Change (YoY)	+38.73%
Shares Change (QoQ)	-48.47%
Owned by Insiders (%)	5.41%
Owned by Institutions (%)	10.32%
Float	7.04M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.37
PB Ratio	1.64
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 3.39, with an EV/FCF ratio of -20.42.

EV / Earnings	-0.58
EV / Sales	0.23
EV / EBITDA	3.39
EV / EBIT	n/a
EV / FCF	-20.42

Financial Position

The company has a current ratio of 1.16, with a Debt / Equity ratio of 1.47.

Current Ratio	1.16
Quick Ratio	0.93
Debt / Equity	1.47
Debt / EBITDA	4.94
Debt / FCF	-29.99
Interest Coverage	-0.15

Financial Efficiency

Return on equity (ROE) is -109.23% and return on invested capital (ROIC) is -0.62%.

Return on Equity (ROE)	-109.23%
Return on Assets (ROA)	-0.22%
Return on Invested Capital (ROIC)	-0.62%
Return on Capital Employed (ROCE)	-0.73%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	560,741
Profits Per Employee	-218,809
Employee Count	83
Asset Turnover	0.53
Inventory Turnover	2.10

Taxes

In the past 12 months, Aytu BioPharma has paid 234,045 in taxes.

Income Tax	234,045
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-34.72%
50-Day Moving Average	1.61
200-Day Moving Average	2.41
Relative Strength Index (RSI)	71.86
Average Volume (20 Days)	2,207

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Aytu BioPharma had revenue of GBP 46.54 million and -18.16 million in losses. Loss per share was -2.24.

Revenue	46.54M
Gross Profit	31.11M
Operating Income	-306,859
Pretax Income	-18.01M
Net Income	-18.16M
EBITDA	2.99M
EBIT	-306,859
Loss Per Share	-2.24

Balance Sheet

The company has 22.31 million in cash and 15.55 million in debt, with a net cash position of 6.76 million.

Cash & Cash Equivalents	22.31M
Total Debt	15.55M
Net Cash	6.76M
Net Cash Per Share	n/a
Equity (Book Value)	10.55M
Book Value Per Share	0.98
Working Capital	7.93M

Cash Flow

In the last 12 months, operating cash flow was -442,085 and capital expenditures -76,529, giving a free cash flow of -518,614.

Operating Cash Flow	-442,085
Capital Expenditures	-76,529
Free Cash Flow	-518,614
FCF Per Share	n/a

Margins

Gross margin is 66.84%, with operating and profit margins of -0.66% and -39.02%.

Gross Margin	66.84%
Operating Margin	-0.66%
Pretax Margin	-38.70%
Profit Margin	-39.02%
EBITDA Margin	6.43%
EBIT Margin	-0.66%
FCF Margin	n/a

Dividends & Yields

Aytu BioPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-38.73%
Shareholder Yield	-38.73%
Earnings Yield	-104.93%
FCF Yield	-3.00%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on January 6, 2023. It was a reverse split with a ratio of 0.05.

Last Split Date	Jan 6, 2023
Split Type	Reverse
Split Ratio	0.05

Scores

Altman Z-Score	n/a
Piotroski F-Score	3